As part of its 2020 strategy to expand the capabilities of its Active Beauty business, Givaudan today announced that it has reached an agreement to acquire the cosmetics business of Indena.
Headquartered in Milan Italy, Indena is a world leading company dedicated to the identification, development and production of high quality active ingredients derived from plants, for use in the pharmaceutical, health food and personal care industries. With almost a century of botanical experience, Indena has developed an extensive breadth of expertise in this field, while ensuring biodiversity and protecting the ecosystem from uncontrolled harvesting, according to the companies.
Givaudan and Indena will also sign a long term partnership agreement under which Indena will continue to manufacture ingredients for Givaudan, as well as providing innovation capabilities and other supporting services. This partnership will allow both companies to enhance their capabilities and to focus on their respective core competencies, a win-win strategy to the benefit of customers and consumers.
Maurizio Volpi, President of Givaudan’s Fragrance Division says: “The acquisition of the cosmetics business of Indena fits very well with our long term strategy for Active Beauty. They have an excellent reputation in the market, thanks to the quality of their ingredients, their strong focus on innovation as well as the mastering of their supply chain. It offers Active Beauty an expanded portfolio of plant-based ingredients that nicely complement our current portfolio.
Daniele Giavini, Managing Director of Indena, adds: “We are in favour of this transaction as it enables Indena to focus on its core markets of pharmaceuticals and health food, whilst continuing to support the cosmetic ingredients business.”
The terms of the deal have not been disclosed and Givaudan plans to fund the transaction from existing resources. Indena’s cosmetic ingredients business would have represented approximately EUR 8 million of incremental sales to Givaudan’s results in 2018 on a proforma basis. The transaction is expected to close in Q1 2020.